Labour market · 22/10/20261 min read
Georgiamune and Menarini Group enter into an exclusive global license and collaboration agreement for GIM-621, a first-in-class oral immuno-oncology agent
Summary
GIM-621 is a preclinical stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors.
Original source language: PR Newswire UK — News ReleasesOpen original release →